Clinical consequences of resistant Candida infections in intensive care.
Many issues need to be addressed by the Intensive Care Unit physician in the decision-making process regarding antifungal therapy for Candida infection, most importantly pharmacokinetic concerns and/or organ failure limitations. In addition, the extensive use of antifungal agents can select for Candida spp. that exhibit decreased susceptibility to these agents. However, the risk appears low, even in the case of prophylactic or pre-emptive antifungal therapy, but this needs to be confirmed in large-scale studies.
Montravers
Philippe
P
Department of Anaesthesia and Surgical Intensive Care Unit, Assistance Publique-Hopitaux de Paris, Hôpital Bichat Claude Bernard-Université Paris 7, France. philippe.montravers@bch.aphp.fr
Jabbour
Khalil
K
D019072:Antibiotic Prophylaxis; D000935:Antifungal Agents / Q000494:pharmacology / Q000627:therapeutic use; D002177:Candidiasis / Q000188:drug therapy* / Q000453:epidemiology* / Q000209:etiology; D003428:Cross Infection; D025141:Drug Resistance, Fungal; D015725:Fluconazole / Q000494:pharmacology / Q000627:therapeutic use; D017408:Guidelines as Topic; D006801:Humans; D007362:Intensive Care Units; D017093:Liver Failure / Q000150:complications; D051437:Renal Insufficiency / Q000150:complications
D000935:Antifungal Agents; D015725:Fluconazole